Seems to be an interesting site; however, no search engine for data within its structure. Stumbled across one Xoma comment, but nothing really worth posting.
prous.es
-----------------------------------------
Old news story mentioning Xoma and others
Second Generation Products and Novel Therapeutics Drive Respiratory Markets
August 25, 1997 2:34 PM EDT
FOSTER CITY, Calif., Aug. 25 /PRNewswire/ -- The worldwide respiratory therapeutics market is expected to grow steadily into 2005, with the exception of a slight slowing in 1997, caused by intense competition among bronchodilators due to generic competition and slight growth rate dips among the anti-inflammatories for chronic obstructive pulmonary disease (COPD) and allergy therapeutics. The market is expected to improve in coming years as second generation products and novel therapeutics with improved efficacy and reduced side effects reach the market.
Market dynamics over the next few years will be most affected by managed care practices, OTC product switching, generic competition, changes in pulmonary delivery systems, and patient population growth, according to a new strategic market assessment study recently published by Front Line Strategic Management Consulting, Inc.
As the patient populations for asthma, chronic bronchitis, emphysema and allergic rhinitis continue to rise, so will the demand for respiratory therapeutics. The worldwide respiratory market is expected to be dominated by three drug classes: allergy therapeutics, bronchodilators, and anti-inflammatories used for treating various forms of COPD. The prevalence of the active diseases, combined with relatively high drug prices, enables these three classes to dominate the market. By 2005, the relative breakdown of the market is not expected to change significantly. Generic competition will likely impact bronchodilators while novel drugs are expected to enter all of the markets, thereby lessening the negative effects of price competition among the off-patent products.
There are a number of biotechnology and pharmaceutical companies involved in the RDS and anti-tubercular fields. Besides the large pharmaceutical players, companies like PathoGenesis, MicroLogic, Cypros Pharmaceutical, CytRx, Cell Genesys, Chisei, Forum Products, Scios Nova, Transcend Therapeutics, NexStar, and Xoma to name a few, currently have products or have products in development for these indications.
Front Line Strategic Management Consulting, Inc., is a management consulting firm specializing in the pharmaceutical and biotechnology industries, providing its clients with strategic evaluations, recommendations and competitive assessments. This research was obtained and analyzed in its 1997 multi-client report, Respiratory Therapeutics and Diseases: A Strategic Evaluation and Competitive Assessment. SOURCE Front Line Strategic Management Consulting Inc.
c PR Newswire. All rights reserved. |
